VWM
CRSP icon

Valley Wealth Managers’s CRISPR Therapeutics CRSP Stock Holding History

Valley Wealth Managers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 344
2026
Q1 		– Hold
0
– – – 316
2025
Q4 		– Hold
0
– – – 356
2025
Q3 		– Hold
0
– – – 305
2025
Q2 		– Hold
0
– – – 302
2025
Q1 		– Hold
0
– – – 375
2024
Q4 		– Hold
0
– – – 402
2024
Q3 		– Hold
0
– – – 405
2024
Q2 		– Hold
0
– – – 379
2024
Q1 		– Hold
0
– – – 319
2023
Q4 		– Hold
0
– – – 337
2023
Q3 		– Hold
0
– – – 367
2023
Q2 		– Hold
0
– – – 338
2023
Q1 		– Hold
0
– – – 358
2022
Q4 		– Sell
-12
Closed -$637 – 365
2022
Q3 		$1K Buy
+12
New +$870 ﹤0.01% 390

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Valley Wealth Managers's CRSP Position: Q2 2026 in Review

Valley Wealth Managers held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 0 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #344.

Valley Wealth Managers first reported a position in CRSP in Q3 2022 and has held it in 1 quarter since. The position peaked at $1K in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Valley Wealth Managers held 0 shares of CRISPR Therapeutics worth $12 as of Q2 2026.
  • Valley Wealth Managers left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Valley Wealth Managers's portfolio in Q2 2026, its #344 holding.
  • Valley Wealth Managers first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 1 quarter since.
  • Valley Wealth Managers's CRISPR Therapeutics position peaked at $1K in Q3 2022.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Valley Wealth Managers's 13F filing for Q2 2026, filed 4 Aug 2026.